![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Deep sequencing analysis of rilpivirine virologic failures in the Phase III studies ECHO and THRIVE shows no association with the presence of minority resistance-associated variants at baseline
|
|
|
Reported by Jules Levin
International Workshop on HIV & Hepatitis Virus
Drug Resistance and Curative Strategies,
Melia Sitges, Spain, 5-9 June 2012
Veerle Van Eygen,1 Kim Thys,1 Johan Vingerhoets,1 Carl Van Hove,2 Laurence T Rimsky,1 Jeroen Aerssens,1 Gaston R Picchio3
1Janssen Infectious Diseases BVBA, Beerse, Belgium; 2Janssen Pharmaceutica, Beerse, Belgium; 3Janssen Research & Development LLC, Titusville, NJ, USA
![resistance1.gif](../images/062612/062612-1/resistance1.gif)
![resistance2.gif](../images/062612/062612-1/resistance2.gif)
![resistance3.gif](../images/062612/062612-1/resistance3.gif)
![resistance4.gif](../images/062612/062612-1/resistance4.gif)
![resistance5.gif](../images/062612/062612-1/resistance5.gif)
![resistance6.gif](../images/062612/062612-1/resistance6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|